Shares of pharmaceutical giant Eli Lilly & Co. declined sharply following an unexpected regulatory update from the U.S. Food and Drug Administration (FDA). The agency has extended its review timeline for the company’s oral weight-loss drug candidate, orforglipron, pushing the decision date to April 2026. This represents a significant postponement from the late March target that had been anticipated by the market. Investor reaction was swift, with Eli Lilly’s stock closing down 3.8% on Thursday amid elevated trading volume. This development is seen as granting a clear advantage to its main competitor, Novo Nordisk.
A Setback in a High-Stakes Market
Orforglipron is an investigational, once-daily GLP-1 receptor agonist positioned to capture a share of the multi-billion dollar obesity treatment market. In a bid to expedite the process, Eli Lilly had submitted a National Priority Review Voucher, a mechanism designed to shorten the standard FDA review period of 10-12 months down to just one or two months. Despite this, the regulatory body has opted for a lengthier evaluation timeframe.
This delay offers Novo Nordisk a valuable strategic window. The Danish rival already markets an oral anti-obesity medication, Wegovy, and can now solidify its position with patients who prefer pills over injectable therapies. Market experts had previously projected that Eli Lilly would rapidly gain ground upon receiving approval for its own oral treatment.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Underlying Strength Amidst Temporary Headwind
The revised regulatory schedule arrives during a period of considerable momentum for Eli Lilly. In 2025, the company ascended to become the world’s most valuable pharmaceutical firm, powered largely by the robust performance of its injectable GLP-1 therapies, Zepbound and Mounjaro. Speaking at the J.P. Morgan Healthcare Conference in early January, CEO David Ricks had projected a swift review and a potential market launch in the second quarter of 2026.
Many industry analysts view this regulatory extension as a near-term obstacle rather than a long-term threat. The global obesity market is forecast to expand to a staggering $150 billion by 2035, a potential that continues to underpin Eli Lilly’s sustained growth narrative. The company is concurrently advancing a broad pipeline of other projects, including the early-stage drug olomorasib, for which it provided updates on January 15.
All Eyes on April 2026
The new critical date for investors is now April 10, 2026. Despite the setback, the majority of research analysts maintain a “Strong Buy” rating on Eli Lilly’s equity. The coming months will reveal whether the company can leverage the additional time to secure a compelling approval and how the competitive landscape in the fiercely contested GLP-1 sector will continue to evolve.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from January 18 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 18.
Eli Lilly: Buy or sell? Read more here...
